Ulla Mandel
8Patents
3h-index
8Co-inventors
46Inventor score
Filing activity: Oct 4, 2007 → Jun 18, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8440798B2 | Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies | Emerging Cross-Sectional Technologies | 19 | Active |
| US8912311B2 | Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies | Emerging Cross-Sectional Technologies | 6 | Active |
| US9359436B2 | Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies | Emerging Cross-Sectional Technologies | 4 | Active |
| US10139414B2 | Tn-MUC4 binding polypeptides and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US10919973B2 | Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies | Emerging Cross-Sectional Technologies | 2 | Active |
| US11067578B2 | Tn-MUC4 binding polypeptides and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US10017576B2 | Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US11860165B2 | CORE3-MUC1 binding polypeptides and uses thereof | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.